RPRX · Royalty Pharma plc
$58.60
+0.04 (+0.07%)
At close · Aug 14
Market Cap
$33.70B
Shares
575.00M
Royalty Pharma plc Earnings Call Transcripts
Every quarterly earnings call for Royalty Pharma plc (RPRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼2.1%
$573.46M
$142.65M
'22 Q3
22-11-08
▼1.7%
$565.75M
−$456.08M
'22 Q4
23-01-09
▲21.7%
$683.97M
$340.75M
'23 Q1
23-05-09
▲0.4%
$538.20M
$227.62M
'23 Q2
23-08-08
▼6.5%
$536.31M
$72.11M
'23 Q3
23-11-08
▲5.4%
$596.07M
$494.34M
'23 Q4
24-02-15
▼17%
$567.98M
$4.78M
'24 Q1
24-05-09
▼0.2%
$537.27M
$102.00M
'24 Q2
24-08-08
▲5.3%
$564.69M
$543.99M
'24 Q3
24-11-06
▼0.4%
$593.64M
$208.21M
'24 Q4
25-01-10
▲0%
$568.25M
$239.35M
'25 Q1
25-05-08
▲7.7%
$578.66M
$32.18M
'25 Q2
25-08-06
▲7.9%
$609.29M
$288.22M
'25 Q3
25-11-05
▲4.8%
$621.99M
$211.21M
'25 Q4
26-02-11
▲11%
$630.58M
$294.69M
'26 Q1
26-05-06
LATEST
▲16.5%
$674.14M
$17.88M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Royalty Pharma Q2 2026 Financial Results Call
Revenue
$674.14M
▲ 16.5% YoY Diluted EPS
$0.04
▼ 42.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Royalty Pharma at the Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Royalty Pharma plc Q1 FY2026 Earnings Call
Confident tone
R&D Co-Funding
Portfolio Receipts Growth
Clinical and Regulatory Updates
Revenue
$630.58M
▲ 11% YoY Diluted EPS
$0.67
▲ 21.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-03
Royalty Pharma at TD Cowen’s 46th Annual Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-11
Royalty Pharma plc Q4 FY2025 Earnings Call
Confident tone
Financial performance and growth
Transaction pipeline and synthetic royalties
Capital deployment and shareholder returns
Revenue
$621.99M*
▲ 4.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-13
Royalty Pharma at the 44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-12-03
Royalty Pharma at the 8th Annual Evercore Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-05
Royalty Pharma plc Q3 FY2025 Earnings Call
Confident tone
LP(a) clinical program (olpacican/alpacoran)
Portfolio receipts and top-line growth
Returns on capital
Revenue
$609.29M
▲ 7.9% YoY Diluted EPS
$0.67
▼ 44.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Royalty Pharma plc Q2 FY2025 Earnings Call
Confident tone
Portfolio Receipts growth and guidance raise
Clinical and product news across portfolio
External manager acquisition / internalization
Revenue
$578.66M
▲ 7.7% YoY Diluted EPS
$0.07
▼ 69.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Royalty Pharma plc Q1 FY2025 Earnings Call
Confident tone
Financial Performance and Guidance
Litifilimab / Biogen Partnership
Capital Allocation and Share Repurchases
Revenue
$568.25M
▲ 0% YoY Diluted EPS
$0.55
▲ 5400% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Royalty Pharma plc Q4 FY2024 Earnings Call
Confident tone
Portfolio Receipts and financial performance
Internalization of external manager
Capital deployment and share repurchases
Revenue
$593.64M*
▼ 0.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Royalty Pharma plc Q3 FY2024 Earnings Call
Confident tone
Syndax / Niktimvo Deal
Portfolio Receipts Growth
Portfolio Products and Approvals
Revenue
$564.69M
▲ 5.3% YoY Diluted EPS
$1.21
▲ 656.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Royalty Pharma plc Q2 FY2024 Earnings Call
Confident tone
Portfolio receipts growth and raised guidance
Voranigo acquisition and commercial launch
Repeat business and partnership relationships
Revenue
$537.27M
▼ 0.2% YoY Diluted EPS
$0.23
▼ 54% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Royalty Pharma plc Q1 FY2024 Earnings Call
Confident tone
Frexalimab acquisition
Development-stage pipeline
Financial results and guidance
Revenue
$567.98M
▼ 17% YoY Diluted EPS
$0.01
▼ 98.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Royalty Pharma plc Q4 FY2023 Earnings Call
Confident tone
Portfolio growth and acquisitions
Financial performance and 2024 guidance
Tysabri biosimilar exposure
Revenue
$596.07M*
▲ 5.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Royalty Pharma plc Q3 FY2023 Earnings Call
Revenue
$536.31M
▼ 6.5% YoY Diluted EPS
$0.16
▼ 50% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Royalty Pharma plc Q2 FY2023 Earnings Call
Revenue
$538.20M
▲ 0.4% YoY Diluted EPS
$0.50
▼ 28.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Royalty Pharma plc Q1 FY2023 Earnings Call
Revenue
$683.97M
▲ 21.7% YoY Diluted EPS
$0.76
▲ 533.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Royalty Pharma plc Q4 FY2022 Earnings Call
Revenue
$565.75M*
▼ 1.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Royalty Pharma plc Q3 FY2022 Earnings Call
Revenue
$573.46M
▼ 2.1% YoY Diluted EPS
$0.32
▲ 33.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Royalty Pharma plc Q2 FY2022 Earnings Call
Revenue
$535.96M
▼ 3.4% YoY Diluted EPS
$0.70
▼ 35.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Royalty Pharma plc Q1 FY2022 Earnings Call
Revenue
$562.05M
▼ 1.9% YoY Diluted EPS
$0.12
▼ 33.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Royalty Pharma plc Q4 FY2021 Earnings Call
Revenue
$575.70M*
▲ 0.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Royalty Pharma plc Q3 FY2021 Earnings Call
Revenue
$585.77M
▲ 8.8% YoY Diluted EPS
$0.24
▼ 69.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Royalty Pharma plc Q2 FY2021 Earnings Call
Revenue
$554.96M
▲ 8.6% YoY Diluted EPS
$1.08
▲ 1100% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Royalty Pharma plc Q1 FY2021 Earnings Call
Revenue
$573.03M
▲ 14.4% YoY Diluted EPS
$0.18
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Royalty Pharma plc Q4 FY2020 Earnings Call
Revenue
$572.14M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Royalty Pharma plc Q3 FY2020 Earnings Call
Revenue
$538.40M
▲ 16% YoY Diluted EPS
$0.79
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-19
Royalty Pharma plc Q2 FY2020 Earnings Call
Revenue
$510.93M
▲ 11.7% YoY Diluted EPS
$0.09
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–29 of 29 earnings calls
Key facts
CIK
1802768
CUSIP
G7709Q104
13F (30d)
601 filings
593 filers
Visit website
Investor relations